Biotech Co., Ltd. announced that its revenue for the first half of 2026 was 756 million yuan, an increase of 22.09% over the previous year. Net profit attributable to shareholders of listed companies was 104 million yuan, an increase of 72.28% over the previous year. Net profit attributable to shareholders of listed companies in the same period last year was 604.24 million yuan. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 89.6856 million yuan, an increase of 178.61% over the previous year.

Biotech Co., Ltd. announced that its revenue for the first half of 2026 was 756 million yuan, an increase of 22.09% over the previous year. Net profit attributable to shareholders of listed companies was 104 million yuan, an increase of 72.28% over the previous year. Net profit attributable to shareholders of listed companies in the same period last year was 604.24 million yuan. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 89.6856 million yuan, an increase of 178.61% over the previous year.